The first February 2021 report of RECOVERY’s tocilizumab results, written as the announcement and preprint emerged. Simon Carley and Dan Horner outline the reported benefits in hospitalised patients with hypoxia and inflammation, while flagging the need for fuller appraisal and questions about immunosuppression.